Latest California Healthline Stories
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Congress And Health Care. Again.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ Drug Prices And Unicorns
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico, and Erin Mershon of STAT News discuss a series of health policy court decisions on everything from prescription drug discounts to soda taxes. Plus, Rovner, interviews health care futurist and consultant Jeff Goldsmith.
Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy
Some state Medicaid programs are not paying for the procedures, and Medicare’s complicated payment rates have hospitals concerned that it will not cover all the costs.
Gastos de bolsillo impiden que más personas reciban la droga que previene el VIH
Funcionarios de salud pública están intensificando esfuerzos para que más personas puedan consumir PrEP. Pero aseguradoras ponen trabas al uso de cupones.
Out-Of-Pocket Costs Put HIV Prevention Drug Out Of Reach For Many At Risk
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.